Amangul A. Uzbekova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amangul A. Uzbekova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Beyatli
Department of Medicinal and Aromatic Plants, Hamidiye Vocational School of Health Services, University of Health Sciences, Istanbul 34668, Türkiye
1 shared publication - Bayan I. Tursubekova
Department of Chemistry and Pharmaceutical Engineering, Auezov University, Shymkent 160000, Kazakhstan
1 shared publication - Gulnara Kadyrbayeva
School of Pharmacy, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan
1 shared publication - Kaldanay Kozhanova
S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
1 shared publication - Meruyert Amantayeva
School of Pharmacy, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan
1 shared publication - Meruyert I. Tleubayeva
Department of Pharmaceutical Technology, Kazakh National Medical University Named After S.D. Asfendiyarova, Almaty 050000, Kazakhstan
1 shared publication
Latest Publications
- Open Access
Unveiling the Antihyperglycemic Potential of Arctium lappa L. (Asteraceae): Traditional Application, Phytochemistry, and Molecular Insights
Diabetes mellitus is a chronic disease requiring multifunctional natural agents. Arctium lappa is traditionally used in Eastern and European medicine to address metabolic disorders. This comprehensive narrative review, conducted between 2000 and 2025 using international databases (Scopus, PubMed, Web of Science Core Collection, and Google Scholar), evaluates the species through its ethnomedicine, phytochemistry, preclinical evidence, and safety. The available evidence suggests that A. lappa exerts antidiabetic effects via multi-layered mechanisms, including AMPK activation, insulin signaling modulation, and increased GLUT4 translocation. Key bioactives (arctigenin, arctiin, and inulin) collectively improve insulin sensitivity and lipid metabolism. However, preclinical studies confirm these effects in animal models, while limited clinical data in non-diabetic cohorts focus on systemic inflammation. This highlights a significant gap in randomized controlled trials targeting glycemic control in diabetic populations. In this context, while A. lappa shows promise as a potential metabolic regulator; this evidence is currently derived primarily from in vitro and animal models. Systematic clinical trials are urgently required to establish glycemic efficacy in humans, validate its therapeutic potential, and determine the optimal dosage and safety profile. This review evaluates the multi-targeted biological potential of A. lappa to guide future research and evidence-based application.
Open AccessUnveiling the Antihyperglycemic Potential of Arctium lappa L. (Asteraceae): Traditional Application, Phytochemistry, and Molecular Insights
Diabetes mellitus is a chronic disease requiring multifunctional natural agents. Arctium lappa is traditionally used in Eastern and European medicine to address metabolic disorders. This comprehensive narrative review, conducted between 2000 and 2025 using international databases (Scopus, PubMed, Web of Science Core Collection, and Google Scholar), evaluates the species through its ethnomedicine, phytochemistry, preclinical evidence, and safety. The available evidence suggests that A. lappa exerts antidiabetic effects via multi-layered mechanisms, including AMPK activation, insulin signaling modulation, and increased GLUT4 translocation. Key bioactives (arctigenin, arctiin, and inulin) collectively improve insulin sensitivity and lipid metabolism. However, preclinical studies confirm these effects in animal models, while limited clinical data in non-diabetic cohorts focus on systemic inflammation. This highlights a significant gap in randomized controlled trials targeting glycemic control in diabetic populations. In this context, while A. lappa shows promise as a potential metabolic regulator; this evidence is currently derived primarily from in vitro and animal models. Systematic clinical trials are urgently required to establish glycemic efficacy in humans, validate its therapeutic potential, and determine the optimal dosage and safety profile. This review evaluates the multi-targeted biological potential of A. lappa to guide future research and evidence-based application.